Novartis AG – Product Pipeline Review

Global Markets Direct’s, ‘Novartis AG – Product Pipeline Review – 2016’, provides an overview of the Novartis AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Novartis AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Novartis AG

The report provides overview of Novartis AG including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Novartis AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Novartis AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Novartis AG’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Novartis AG

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Novartis AG’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Novartis AG Snapshot 8

Novartis AG Overview 8

Key Information 8

Key Facts 8

Novartis AG - Research and Development Overview 9

Key Therapeutic Areas 9

Novartis AG - Pipeline Review 28

Pipeline Products by Stage of Development 28

Pipeline Products - Monotherapy 29

Pipeline Products - Combination Treatment Modalities 30

Pipeline Products - Partnered Products 31

Pipeline Products - Out-Licensed Products 34

Novartis AG - Pipeline Products Glance 36

Novartis AG - Late Stage Pipeline Products 36

Novartis AG - Clinical Stage Pipeline Products 40

Novartis AG - Early Stage Pipeline Products 49

Novartis AG - Drug Profiles 52

ceritinib 52

dabrafenib mesylate + trametinib dimethyl sulfoxide 55

eltrombopag olamine 57

everolimus 60

serelaxin 66

trametinib dimethyl sulfoxide 69

zoledronic acid 72

imatinib mesylate 74

panobinostat 77

pazopanib hydrochloride 84

(glycopyrrolate + indacaterol maleate + mometasone fuorate) 89

(indacaterol maleate + mometasone furoate) 90

(sacubitril + valsartan) 92

alpelisib 95

bimagrumab 97

buparlisib hydrochloride 99

canakinumab 103

dabrafenib mesylate 106

fevipiprant 109

fingolimod hydrochloride 111

midostaurin 114

nilotinib 116

ofatumumab 120

osilodrostat phosphate 125

oxytocin 127

pasireotide 129

pasireotide ER 132

ranibizumab 134

ribociclib 138

secukinumab 141

siponimod 147

CDZ-173 149

clofazimine 150

CNP-520 151

(dectrekumab + VAK-694) 152

afuresertib hydrochloride 153

aldesleukin 156

BHQ-880 158

BVS-857 160

capmatinib 161

CFZ-533 164

cipargamin 166

CJM-112 167

dectrekumab 168

EGF-816 170

elgemtumab 171

EMA-401 173

FCR-001 175

GSK-2285921 177

HSC-835 179

iloperidone 180

infigratinib 182

KAF-156 183

KRP-203 184

LCL-161 186

LFX-453 188

LHW-090 189

ligelizumab 190

LJN-452 192

LMI-070 193

mavoglurant 194

MCS-110 196

octreotide acetate long acting 197

pradigastat sodium 199

ruxolitinib phosphate 200

selurampanel 205

sonidegib phosphate 206

tesidolumab 210

tisagenlecleucel-T 212

trametinib dimethyl sulfoxide + uprosertib 215

uprosertib 217

VAY-736 218

BZF-961 220

CGF-166 221

CSJ-137 223

CSJ-148 224

FGF-401 225

HDM-201 226

LAG-525 227

lapatinib ditosylate 228

MGB-453 232

PDR-001 233

PIM-447 234

RAF-265 235

sotrastaurin acetate 236

ABL-001 238

AV-380 239

Cellular Immunotherapy to Target c-Met for Oncology 240

Cellular Immunotherapy to Target CD22 for Acute Lymphoblastic Leukemia 241

Cellular Immunotherapy to Target EGFR for Glioblastoma 242

CGM-097 243

CLR-325 244

huCART19 245

IDH-305 246

IMP-701 247

LEQ-506 248

LGK-974 249

LML-134 250

LNA-043 251

LXH-254 252

LXS-196 253

MesoCART 254

NOV-10 255

NOV-11 256

NOV-7 257

NOV-8 258

NOV-9 259

octreotide acetate LAR 260

PBF-509 261

PCA-062 263

QCC-374 264

CART-123 265

Cellular Immunotherapy to Target B-Cell Maturation Factor for Multiple Myeloma 266

Antibody to Inhibit PD-L1 for Oncology 267

AUSRM-057 268

BLZ-945 269

BQS-481 271

BVB-808 272

Cellular Immunotherapy Program for Oncology 273

Cellular Immunotherapy to Target GD2 for Neuroblastoma 274

CHZ-868 275

cosyntropin ER 276

ESK-1 277

GNFPf-5069 278

Kartogenin 279

KR-22809 280

LCZ-960 281

LGB-321 282

LKZ-145 283

LQN-725 284

Monoclonal Antibody to Inhibit CXCR2 for Respiratory Diseases 285

NIBR-0213 286

NITD-349 287

NITD-916 288

NVPQBE-170 289

NVPTNKS-656 290

OXB-302 291

RP-6503 292

Small Molecule to Agonize GPR119 for Type 2 Diabetes 293

Small Molecule to Agonize GPR39 for Type 2 Diabetes 294

Small Molecule to Agonize Nurr1 for Multiple Sclerosis 295

Small Molecule to Inhibit LRRK2 for Parkinson's Disease 296

Small Molecule to Inhibit OX2R for Insomnia 297

Small Molecules to Antagonize VEGFR2 for Solid Tumors 298

Small Molecules to Inhibit Cytochrome bc1 Complex for Tuberculosis 299

Small Molecules to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes 300

Small Molecules to Inhibit Pan PI3K for Ovarian Cancer 301

Small Molecules to Inhibit Pan-RAF Kinase for Oncology 302

Small Molecules to Inhibit Renin for Hypertension 303

XOMA-089 304

ESBA-903 SR 305

LJH-685 306

Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology 307

Small Molecule to Agonize Adrenergic Beta-2 Receptor for COPD 308

Small Molecules for Tuberculosis 309

Small Molecules for Undisclosed Indication 310

Small Molecules to Antagonize NR2B for Depression 311

Small Molecules to Inhibit Acetyl-CoA Carboxylase for Metabolic, Cardiovascular and Infections 312

Small Molecules to Inhibit CFTR for Secretory Diarrhea 313

Small Molecules to Inhibit FPPS for Soft Tissue Cancer 314

Small Molecules to Inhibit PfATP4 for Malaria 315

Small Molecules to Inhibit PI4KIIIbeta for HCV 316

Novartis AG - Pipeline Analysis 317

Novartis AG - Pipeline Products by Target 317

Novartis AG - Pipeline Products by Route of Administration 330

Novartis AG - Pipeline Products by Molecule Type 331

Novartis AG - Pipeline Products by Mechanism of Action 332

Novartis AG - Recent Pipeline Updates 342

Novartis AG - Dormant Projects 436

Novartis AG - Discontinued Pipeline Products 443

Novartis AG - Discontinued Pipeline Products 443

Discontinued Pipeline Product Profiles 445

Novartis AG - Company Statement 457

Novartis AG - Locations And Subsidiaries 458

Head Office 458

Other Locations & Subsidiaries 458

Appendix 475

Methodology 475

Coverage 475

Secondary Research 475

Primary Research 475

Expert Panel Validation 475

Contact Us 475

Disclaimer 476

List of Tables

List of Tables

Novartis AG, Key Information 21

Novartis AG, Key Facts 21

Novartis AG – Pipeline by Indication, 2016 23

Novartis AG – Pipeline by Stage of Development, 2016 41

Novartis AG – Monotherapy Products in Pipeline, 2016 42

Novartis AG – Combination Treatment Modalities in Pipeline, 2016 43

Novartis AG – Partnered Products in Pipeline, 2016 44

Novartis AG – Partnered Products/ Combination Treatment Modalities, 2016 45

Novartis AG – Out-Licensed Products in Pipeline, 2016 47

Novartis AG – Out-Licensed Products/ Combination Treatment Modalities, 2016 48

Novartis AG – Pre-Registration, 2016 49

Novartis AG – Filing rejected/Withdrawn, 2016 50

Novartis AG – Phase III, 2016 51

Novartis AG – Phase II, 2016 53

Novartis AG – Phase I, 2016 57

Novartis AG – Phase 0, 2016 61

Novartis AG – Preclinical, 2016 62

Novartis AG – Discovery, 2016 64

Novartis AG – Pipeline by Target, 2016 330

Novartis AG – Pipeline by Route of Administration, 2016 343

Novartis AG – Pipeline by Molecule Type, 2016 344

Novartis AG – Pipeline Products by Mechanism of Action, 2016 345

Novartis AG – Recent Pipeline Updates, 2016 355

Novartis AG – Dormant Developmental Projects,2016 449

Novartis AG – Discontinued Pipeline Products, 2016 456

Novartis AG, Subsidiaries 471

List of Figures

List of Figures

Novartis AG – Pipeline by Top 10 Indication, 2016 23

Novartis AG – Pipeline by Stage of Development, 2016 41

Novartis AG – Monotherapy Products in Pipeline, 2016 42

Novartis AG – Combination Treatment Modalities in Pipeline, 2016 43

Novartis AG – Partnered Products in Pipeline, 2016 44

Novartis AG – Out-Licensed Products in Pipeline, 2016 47

Novartis AG – Pipeline by Top 10 Target, 2016 330

Novartis AG – Pipeline by Top 10 Route of Administration, 2016 343

Novartis AG – Pipeline by Top 10 Molecule Type, 2016 344

Novartis AG – Pipeline Products by Top 10 Mechanism of Action, 2016 345

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports